Ahnemark, E.
Di Schiena, M.
Fredman, A.-C.
Medin, E.
Söderling, J. K.
Ginsberg, Y.
Article History
Received: 6 February 2018
Accepted: 27 June 2018
First Online: 13 July 2018
Ethics approval and consent to participate
: The study was approved by the Regional Ethical Review Board in Stockholm and the need for consent was waived due to the retrospective nature of the study. The study was conducted in accordance with the ethical standards of the World Medical Association Declaration of Helsinki. The data-gathering form was based on the recommendations for neuropsychiatric investigations of patients with suspected ADHD described in recent guidelines (ExternalRef removed) and validated by a clinical expert.
: Not applicable.
: Dr. Ewa Ahnemark is an employee of Shire and owns stock or stock options. The following authors have received compensation for serving as consultants or speakers for, or they or the institutions they work for have received research support or royalties from, the companies or organizations indicated: Dr. Marianne Di Schiena (Prima Child and Adult Psychiatry AB); Dr. Anne-Christine Fredman (Evolan, Lilly, Novartis, Servier, and Shire); Dr. Emma Medin (PAREXEL International); Dr. Jonas. K. Söderling (COMBINE Sweden, Novo Nordisk, and PAREXEL International); Dr. Ylva Ginsberg (Eli Lilly, HB Pharma, Janssen-Cilag, Lundbeck, and Novartis).
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.